HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:
Operating profit/loss of SEK 156.0 m Today, Medivir AB (STO:MVIRB)(OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its Interim Report for the period 1 January – 30 September and its operational report for the third quarter of 2011.
